STF-3600
STF-3600 is a LRRK2G2019S inhibitor with an IC50 of 0.9 nM against the human target. It has oral activity and can cross the blood-brain barrier. STF-3600 selectively inhibits kinase activity, including autophosphorylation at Ser935 and Ser1292, as well as phosphorylation of the endogenous substrate Rab10 at Thr73. STF-3600 inhibits vacuolization of type II pulmonary epithelial cells in wild-type/heterozygous mice, while it induces this vacuolization phenotype in homozygous mice. STF-3600 can be used in Parkinson's disease research.
For research use only. We do not sell to patients.
- CAS No.: 2765654-79-1
- Formula: C24H21N5
- Molecular Weight:379.46
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
LRRK2G2019S 0.9 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
2.1 nM
|
Inhibition of pSer935 LRRK2 in HEK293 cells stably expressing human G2019S LRRK2 incubated for 2 hrs measured by CisBio phospho-LRRK2 (Ser935) kit assay.
Inhibition of pSer935 LRRK2 in HEK293 cells stably expressing human G2019S LRRK2 incubated for 2 hrs measured by CisBio phospho-LRRK2 (Ser935) kit assay.
|
42503786 |
| HEK293 | IC50 |
140 nM
|
Inhibition of pSer935 LRRK2 in HEK293 cells stably expressing human WT LRRK2 incubated for 2 hrs measured by CisBio phospho-LRRK2 (Ser935) kit assay.
Inhibition of pSer935 LRRK2 in HEK293 cells stably expressing human WT LRRK2 incubated for 2 hrs measured by CisBio phospho-LRRK2 (Ser935) kit assay.
|
42503786 |
| HEK293 | IC50 |
2.0 nM
|
Inhibition of pSer1292 LRRK2 in HEK293 cells stably expressing human G2019S LRRK2 incubated for 2 hrs measured by MSD assay.
Inhibition of pSer1292 LRRK2 in HEK293 cells stably expressing human G2019S LRRK2 incubated for 2 hrs measured by MSD assay.
|
42503786 |
| HEK293 | IC50 |
38 nM
|
Inhibition of pSer1292 LRRK2 in HEK293 cells stably expressing human WT LRRK2 incubated for 2 hrs measured by MSD assay.
Inhibition of pSer1292 LRRK2 in HEK293 cells stably expressing human WT LRRK2 incubated for 2 hrs measured by MSD assay.
|
42503786 |
| A549 | IC50 |
6 nM
|
Inhibition of pThr73 Rab10 in human lung epithelial A549 cells expressing G2019S LRRK2 incubated for 2 hrs measured by plate reader assay with acceptor and donor mixes.
Inhibition of pThr73 Rab10 in human lung epithelial A549 cells expressing G2019S LRRK2 incubated for 2 hrs measured by plate reader assay with acceptor and donor mixes.
|
42503786 |
| A549 | IC50 |
41 nM
|
Inhibition of pThr73 Rab10 in human lung epithelial A549 cells expressing WT LRRK2 incubated for 2 hrs measured by plate reader assay with acceptor and donor mixes.
Inhibition of pThr73 Rab10 in human lung epithelial A549 cells expressing WT LRRK2 incubated for 2 hrs measured by plate reader assay with acceptor and donor mixes.
|
42503786 |
In Vitro
STF-3600 (2 h) potently inhibits pSer935 in HEK293 cells expressing LRRK2G2019S, with an IC50 of 2.1 nM[1].
STF-3600 (2 h) potently inhibits pSer1292 in HEK293 cells expressing LRRK2G2019S, with an IC50 of 2 nM[1].
STF-3600 (2 h) inhibits pThr73 Rab10 in A549 cells expressing LRRK2G2019S, with an IC50 of 6 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
In Vivo
STF-3600 (100 mg/kg/day; oral administration; daily dosing for 21 consecutive days) inhibits LRRK2G2019S in the brain tissues of heterozygous and homozygous knock-in mice. It does not induce pulmonary toxicity in wild-type or heterozygous mice, but causes pulmonary vacuolization in homozygous knock-in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice (male and female, 5-8 months old; wild-type, heterozygous G2019S LRRK2 knock-in, and homozygous G2019S LRRK2 knock-in)[1]
-
Dosage:3 mg/kg; 10 mg/kg; 30 mg/kg; 100 mg/kg
-
Administration:p.o.; single dose
-
Result:Achieved maximal inhibition of pSer935 LRRK2 at 10 mg/kg in homozygous G2019S LRRK2 knock-in mouse brain and lung.
Left pSer935 LRRK2 still detectable at 100 mg/kg in wild-type mice.
Showed greater potency of pThr73 Rab10 inhibition in lung tissue of homozygous G2019S LRRK2 knock-in mice compared to wild-type mice.
Left total LRRK2 and Rab10 levels unchanged in all tissues.
-
Animal Model:C57BL/6J mice (male and female, 5-8 months old; wild-type, heterozygous G2019S LRRK2 knock-in, and homozygous G2019S LRRK2 knock-in)[1]
-
Dosage:100 mg/kg/day (actual average exposure 61.6 mg/kg/day)
-
Administration:p.o.; daily; 21 days
-
Result:Induced overt type II pneumocyte vacuolization in homozygous G2019S LRRK2 knock-in mice (112 vacuolated cells per scanned area), with no vacuolization in wild-type or heterozygous G2019S LRRK2 knock-in mice.
Reduced pSer935 LRRK2 activity to ~15% of vehicle-treated levels in homozygous knock-in mouse brain and ~50% of vehicle-treated levels in heterozygous knock-in mouse brain, with no significant effect in wild-type mouse brain.
Caused no significant changes in complete blood count measures across any genotype or gender.
Chemical Information
-
CAS No. 2765654-79-1
-
Molecular Weight 379.46
-
Formula C24H21N5
-
SMILES
CC1=CC(C2=NNC3=CC=C(C=C23)N[C@@H]4C5=CC=C(C#N)C=C5CCC4)=CC=N1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)